ACRO advocates as the collective voice of innovative clinical research and technology organizations to regulators and policymakers, educating stakeholders and shaping policies that foster efficient, effective, and safe conduct of clinical research. Since our founding in 2002, ACRO has been committed to strengthening public understanding and confidence in clinical research. ACRO’s membership has evolved from being comprised entirely of global CROs to now including several of the industry’s technology partners. ACRO looks to demonstrate the important contribution that CROs and technology companies make as partners in the development of new medicines and new treatments. The association is a leading voice for safe and ethical clinical trials, working with stakeholders globally to explore new paradigms for research and development and to promote a more innovative, safe, and efficient clinical trial process. As an association, we are especially interested in areas such as the expansion of the adoption of DCTs, RBQM, diversity and inclusion in clinical trials, enhancing the efficiency of R&D, data sharing, data protection and privacy, technology innovation, real-world evidence, patient-centered drug development, safety and ethics in clinical research, tax policies that support research and innovation, and a host of global regulatory issues.